KR20170025363A - Composition for improving skin - Google Patents
Composition for improving skin Download PDFInfo
- Publication number
- KR20170025363A KR20170025363A KR1020150121704A KR20150121704A KR20170025363A KR 20170025363 A KR20170025363 A KR 20170025363A KR 1020150121704 A KR1020150121704 A KR 1020150121704A KR 20150121704 A KR20150121704 A KR 20150121704A KR 20170025363 A KR20170025363 A KR 20170025363A
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- composition
- extract
- stem cells
- soybean
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 66
- 210000000130 stem cell Anatomy 0.000 claims abstract description 59
- 230000000694 effects Effects 0.000 claims abstract description 31
- 239000002537 cosmetic Substances 0.000 claims abstract description 24
- 230000036560 skin regeneration Effects 0.000 claims abstract description 23
- 235000013305 food Nutrition 0.000 claims abstract description 21
- 230000001737 promoting effect Effects 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 8
- 239000000284 extract Substances 0.000 claims description 38
- 235000013527 bean curd Nutrition 0.000 claims description 25
- 235000020712 soy bean extract Nutrition 0.000 claims description 22
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 239000004480 active ingredient Substances 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 5
- 230000004663 cell proliferation Effects 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 230000014759 maintenance of location Effects 0.000 claims description 2
- 230000001172 regenerating effect Effects 0.000 claims description 2
- RQXXCWHCUOJQGR-UHFFFAOYSA-N 1,1-dichlorohexane Chemical compound CCCCCC(Cl)Cl RQXXCWHCUOJQGR-UHFFFAOYSA-N 0.000 claims 1
- 239000012046 mixed solvent Substances 0.000 claims 1
- 239000012454 non-polar solvent Substances 0.000 claims 1
- 239000002798 polar solvent Substances 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 abstract description 19
- 230000035755 proliferation Effects 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 7
- 235000010518 Canavalia gladiata Nutrition 0.000 abstract description 2
- 235000010520 Canavalia ensiformis Nutrition 0.000 abstract 1
- 240000001723 Entada phaseoloides Species 0.000 abstract 1
- 229940069765 bean extract Drugs 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 51
- 238000009472 formulation Methods 0.000 description 23
- 239000000306 component Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 210000002615 epidermis Anatomy 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- -1 derivatives thereof Substances 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 244000068988 Glycine max Species 0.000 description 5
- 235000010469 Glycine max Nutrition 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 206010057190 Respiratory tract infections Diseases 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 238000010609 cell counting kit-8 assay Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 210000002514 epidermal stem cell Anatomy 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 210000003780 hair follicle Anatomy 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000023895 stem cell maintenance Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 239000004902 Softening Agent Substances 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000012754 barrier agent Substances 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 210000003981 ectoderm Anatomy 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000004088 foaming agent Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000003495 polar organic solvent Substances 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 240000003049 Canavalia gladiata Species 0.000 description 1
- 101710115642 Canavalin Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 102000000426 Integrin alpha6 Human genes 0.000 description 1
- 108010041100 Integrin alpha6 Proteins 0.000 description 1
- 102000012355 Integrin beta1 Human genes 0.000 description 1
- 108010022222 Integrin beta1 Proteins 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 244000086363 Pterocarpus indicus Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 240000001417 Vigna umbellata Species 0.000 description 1
- 235000011453 Vigna umbellata Nutrition 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 239000003004 anti necrotic agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000008278 cosmetic cream Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000009786 epithelial differentiation Effects 0.000 description 1
- 230000008202 epithelial morphogenesis Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000003660 hair regeneration Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000461 neuroepithelial cell Anatomy 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 210000002265 sensory receptor cell Anatomy 0.000 description 1
- 102000027509 sensory receptors Human genes 0.000 description 1
- 108091008691 sensory receptors Proteins 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Medical Informatics (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 피부 재생, 줄기세포 활성 촉진 효과를 나타내는 피부 개선용 조성물에 관한 것이다. The present invention relates to a skin improving composition exhibiting skin regeneration and stem cell activity promoting effect.
발생학적으로 사람 피부의 모든 구성성분은 외배엽이나 중배엽에서 유래되는 것으로 알려져 있다. 표피, 모낭, 피지선 및 땀샘선 등은 외배엽에서 기원하며, 멜라닌 세포, 신경 및 특수 감각 수용체는 신경외배엽에서 유래된다. 발생학적 시기에 따라 배아의 줄기세포는 분화를 거듭하여 각각의 조직 기능에 맞는 특성의 세포가 되고, 성체가 된 후에도 일정수의 줄기세포는 조직에 남게 되는데 피부에서는 주로 두 곳에 줄기세포들이 존재한다. 첫째는 모낭(hair follicle)에 존재한다. 이곳은 세포분화가 일어나기 전의 세포로 표피의 재생과 관련해 중요한 역할을 담당하는 것으로 알려져 있으며, 털의 재생과 성장에도 중요한 역할을 수행하고 있다. 둘째는 표피의 기저층(the basal layer of epidermis)이다. 이곳에 자리하고 있는 줄기세포는 표피는 물론 진피층의 섬유아세포까지 관장하여 피부 건강을 지키는 중요한 역할을 수행하고 있음이 밝혀졌다. 이곳의 줄기세포는 상대적으로 양이 많고 쉽게 얻을 수 있다는 장점이 있어 피부줄기세포 연구에 널리 사용되고 있다. 피부는 지속적으로 재생(renew)되며, 피부의 상피에 존재하는 줄기세포 즉, 피부의 상피줄기세포(epidermal stem cells)는 상처 후 상피의 복구에 관여한다[비특허문헌 7]. 상기 피부의 상피줄기세포는 피부줄기세포(skin stem cells)로도 칭해지며, 상기 피부줄기세포를 활성화시킬 경우, 외상 등의 피부상처를 치료하거나 상처 치료를 촉진할 수 있으며 피부의 주름완화 또한 기대할 수 있다. 피부줄기세포의 지표로는 인테그린β1(integrin β1) 및 인테그린 α6(integrin α6)이 사용되고 있고, 상피 형태 형성 및 분화에 필요한 피부줄기세포의 유지는 p63 단백질에 의해 조절된다고 보고되고 있다. Embryologically, all components of human skin are known to originate from ectoderm or mesodermal lobe. Epidermis, hair follicles, sebaceous glands and glands are originated from ectoderm, and melanocytes, nerves and special sensory receptors are derived from neuroepithelial cells. According to the developmental stage, the embryonic stem cells are repeatedly differentiated and become cells with the characteristics of each tissue function. After the embryo, a certain number of stem cells remain in the tissue. . The first is in the hair follicle. It is known to play an important role in the regeneration of the epidermis into cells before cell differentiation occurs, and plays an important role in hair regeneration and growth. The second is the basal layer of the epidermis. The stem cells found here play an important role in maintaining skin health by administering not only the epidermis but also the fibroblasts of the dermal layer. The stem cells here are relatively large in quantity and easy to obtain, making them widely used in the study of skin stem cells. The skin is constantly renewed, and stem cells present in the epithelium of the skin, that is, epidermal stem cells of the skin, are involved in the repair of the epithelium after injury [Non-Patent Document 7]. The epithelial stem cells of the skin are also referred to as skin stem cells. When the skin stem cells are activated, it is possible to treat skin wounds such as trauma, promote wound healing, have. Integrin β1 and integrin α6 are used as indicators of dermal stem cells, and maintenance of skin stem cells necessary for epithelial morphogenesis and differentiation has been reported to be regulated by p63 protein.
피부줄기세포는 피부의 건강과 생리학적 및 생화학적인 항상성을 유지하는데 중요한 역할을 수행한다. 피부에 존재하는 줄기세포도 노화의 영향으로 인하여 기능에 이상이 발생하게 되고, 이에 따라 피부의 항상성이 깨지면서 여러 가지 문제가 발생된다. 따라서 이러한 줄기세포의 활성을 통하여 피부노화의 여러 현상을 개선할 수 있을 것이다[비특허문헌 8].Dermal stem cells play an important role in maintaining the health and physiological and biochemical homeostasis of the skin. Stem cells present in the skin are also abnormally functioned due to the effect of aging, and thus various problems arise as the homeostasis of the skin is broken. Therefore, it is possible to improve various phenomena of skin aging through the activation of stem cells [Non-Patent Document 8].
또한, 생체에 안전하고, 유효성분이 안정하며, 무엇보다도 기존의 피부 재생 효과가 있는 물질보다 효과가 우수한 피부 재생 활성을 지닌 성분의 개발이 절실히 요망되고 있다.In addition, it is urgently required to develop a composition having a skin regeneration activity that is safe for living body, stable in its effective component, and most effective for a skin regeneration effect.
한편, 작두콩(Canavalia gladiata)은 장미목 콩과에 속하는 한해살이 덩굴성 식물로서, 한방에서는 도두(刀豆)라고 하며 열매가 작두같이 생겼으므로 작두콩이라고 한다. 줄기에 털이 없으며 콩 낟알한 개의 길이가 2~3 cm, 무게가 1.5~3 g으로 콩 종류 중에서 크기가 가장 큰 편이다. 열대 아시아 원산이며 식용으로 재배한다. 작두콩의 색깔은 붉은색 또는 흰색이며, 적색종은 꼬투리를 이용하고, 백색종은 콩을 주로 이용하나 모두 식용 가능하다.. 종자, 껍질, 잎, 줄기, 뿌리 등 모든 부위는 식품소재로 활용될 수 있다.Meanwhile, Canavalia gladiata ) is a perennial plant belonging to the rosewood leguminosae. There are no hairs on the stem, the length of one bean grains is 2 ~ 3 cm and the weight is 1.5 ~ 3 g. It is native to tropical Asia and cultivated for food. The color of red beans is red or white, the red species are pods, and the white species are mainly beans, but they are all edible. All parts such as seeds, bark, leaves, stems and roots are used as food materials. .
작두콩에는 가수분해 효소인 우레아제(urease), 혈구응집소(hemagglutinin), 카나발린(canavalin), 리놀렌산, 사포닌, 콜린, 레시신, 식이 섬유소, 그리고 단백질 등의 다양한 생리활성물질이 함유되어 있는 것으로 알려져 있다. 또한, 염증을 없애는 작용이 뛰어나고 신체의 면역력을 키워주기 때문에 각종 종기나 화농성 질병에 효과가 있으며, 뱃속을 따뜻하게 하고 천식, 가래, 관절염, 신허요통에 효과가 있고, 신장을 튼튼하게 하고 이수작용이 있어 관절염, 변비, 비만증 등을 두루 치료한다고 알려져 있다. 또한 치질, 축농증, 중이염, 위염, 대장염 등에 큰 효과가 있는 것으로 알려져 있어, 기능성 식품 및 의약품 소재로서 주목 받고 있다. Soybean is known to contain various physiologically active substances such as hydrolytic enzymes urease, hemagglutinin, canavalin, linolenic acid, saponin, choline, lecithin, dietary fiber, and protein . In addition, it is effective in eliminating inflammation and enhancing the body's immunity, so it is effective for various boils and purulent diseases, warms the stomach, and is effective for asthma, sputum, arthritis, low back pain, strong kidney, It is known to treat arthritis, constipation, and obesity. It is also known to have a great effect on hemorrhoids, sinusitis, otitis media, gastritis and colitis, and has been attracting attention as a functional food and pharmaceutical material.
작두콩과 관련된 국내특허문헌에는, 등록특허 제0350911호 "도두로부터 분리한 항균 활성 추출물 및 그 제조 방법", 등록특허 제0394584호 "작두콩이 첨가된 두유 및 그 제조방법", 등록특허 제0324132호 "작두콩을 이용한 청국장 및 그의 제조방법", 특허출원 제2002-0055538호 "작두콩과 금송혼합 추출물을 이용한 피부화장료", 특허출원 제2002-0056697호 "도두를 이용한 항선충 제제의 개발", 특허출원 제2001-0031264호 "작두콩 등을 이용한 면역 기능 증강 및 항산화 기능성식품의 개발", 특허출원 제2003-0005294호 "알러지 및 염증 치료용 조성물" 등이 있다.Korean patent documents related to soybean paste include registered patent No. 0350911 entitled " Antimicrobial activity extracts separated from soybean flour and its preparation method ", registered patent No. 0394584 "soybean oil added with soybean curd and its preparation method ", registered patent No. 0324132" Korean Patent Application No. 2002-0055538 entitled "Skin Cosmetics Using Mixed Extracts of Soybean and Golden Rice ", Patent Application No. 2002-0056697" Development of Anti-Necrotic Agents Using Doodul, " 2001-0031264 "Enhancement of Immune Function and Development of Antioxidant Functional Food Using Soybean Paste ", and Patent Application No. 2003-0005294" Composition for treating allergy and inflammation ".
그러나, 작두콩의 줄기세포에 대한 연구는 전무한 실정이다.However, there is no research on stem cell of.
이에, 본 발명자들은 작두콩 추출물이 피부줄기세포의 증식을 촉진하여 피부의 재생을 촉진시키고 줄기세포성 유지 효과를 나타내고 있어 줄기세포 활성 촉진 효과를 확인함으로써 본 발명을 완성하게 되었다.Thus, the present inventors have completed the present invention by confirming the effect of promoting stem cell activation by promoting the proliferation of skin stem cells, promoting regeneration of skin, and exhibiting stem cell maintenance effect.
따라서, 본 발명의 목적은 작두콩 추출물을 유효성분으로 포함하는 피부 재생용 조성물을 제공하는데 있다.Accordingly, an object of the present invention is to provide a composition for skin regeneration, which comprises soybean extract as an active ingredient.
또한, 본 발명의 다른 목적은 작두콩 추출물을 유효성분으로 포함하는 줄기세포 활성 촉진용 조성물을 제공하는데 있다.Another object of the present invention is to provide a composition for stimulating stem cell activity, which comprises soybean extract as an active ingredient.
상기 과제를 해결하기 위한 수단으로서, 본 발명은 의약, 화장료 또는 식품 제조를 위한, 작두콩 추출물을 유효성분으로 포함하는 피부 재생용 조성물을 제공한다.As a means for solving the above problems, the present invention provides a skin regeneration composition comprising, as an active ingredient, a soybean curd extract for the production of medicines, cosmetics or foods.
상기 과제를 해결하기 위한 다른 수단으로서, 본 발명은 화장료 제형 제조를 위한, 작두콩 추출물을 유효성분으로 포함하는 줄기세포 활성 촉진용 조성물을 제공한다.As another means for solving the above problems, the present invention provides a composition for stimulating stem cell activity comprising a soybean curd extract as an active ingredient, for the production of cosmetic formulations.
본 발명에 따른 작두콩 추출물은 피부줄기세포의 증식을 촉진하여 피부의 재생을 촉진시키는 효과를 나타냄으로써, 의약, 화장료 또는 식품 제조에 사용할 수 있다.The extract of soybean curd according to the present invention promotes the proliferation of skin stem cells and promotes the regeneration of the skin, so that it can be used for the production of medicines, cosmetics or foods.
또한, 작두콩 추출물은 피부줄기세포의 증식을 촉진하고, 줄기세포성 유지 효과를 나타내고 있어 줄기세포 활성 촉진용 화장료 제형 제조에 사용할 수 있다. In addition, the extract of soybean curd promotes the proliferation of dermal stem cells and exhibits a stem cell-retaining effect, and thus can be used for the production of cosmetic formulations for promoting stem cell activity.
이하, 본 발명의 구성을 구체적으로 설명한다.Hereinafter, the configuration of the present invention will be described in detail.
피부 재생 성분이 실제 피부에 적용 시 우수한 효과를 발휘하기 위해서는 저농도에서 고활성의 피부 재생 활성을 나타내고, 피부를 투과하여 흡수되는 능력이 우수하고, 피부 재생 효과를 나타내기에 충분한 시간 동안 머무를 수 있도록 휘발성이 낮고, 조성물이나 피부 상에서 활성 성분이 안정하게 유지되고, 의약, 화장료 또는 식품 등으로의 제조가 용이하며, 또한 피부에 안전한 것이 바람직하다. 그러나, 공지의 성분 중 상기 특성을 모두 만족시키는 성분은 흔치 않다. 예를 들어, 몇몇 피부 재생 성분들은 시험관 내 실험 시 저농도에서도 피부 재생 활성은 우수하나, 피부를 투과하여 흡수되는 능력이 떨어져 실제 피부에 적용하기엔 어렵다. 또 다른 활성 성분들은 친수성이 낮아 의약이나 화장품, 식품으로 제형화가 어렵다. 또한, 몇몇 피부 재생 성분들은 열, 광, 또는 산소에 노출되었을 때 상기 활성 성분이 분해되거나 다른 화합물로 변형되어 피부에 적용하기 전에 이미 효과가 사라지는 경우도 있다. In order to exert an excellent effect when the skin regeneration component is applied to actual skin, it is required to exhibit highly regenerated skin activity at a low concentration, have excellent ability to permeate and absorb the skin, Is low and the active ingredient is stably maintained on the composition or on the skin, and it is easy to manufacture into medicines, cosmetics, food or the like, and is safe for the skin. However, the components satisfying all of the above-mentioned characteristics among the known components are not common. For example, some skin regeneration components have excellent skin regeneration activity even at low concentration in vitro, but they are not able to be absorbed through the skin and applied to actual skin. Other active ingredients have low hydrophilicity, making them difficult to formulate into medicines, cosmetics, and foods. In addition, some skin regeneration components may be degraded or transformed into other compounds when exposed to heat, light, or oxygen, which may already have vanished before application to the skin.
하기 실시예에서 확인할 수 있는 바와 같이, 작두콩 추출물은 저농도에서 월등히 우수한 피부 줄기세포 증식 촉진 효과를 나타내므로 피부 재생을 위한 의약, 화장료 또는 식품 조성물의 유효성분으로 사용할 수 있다. As can be seen from the following examples, the extract of soybean curd extract shows remarkably excellent skin stem cell proliferation promoting effect at a low concentration, and thus can be used as an active ingredient of medicines, cosmetics or food compositions for skin regeneration.
따라서, 본 발명은 작두콩 추출물을 유효성분으로 포함하는 피부 재생용 조성물을 제공한다.Accordingly, the present invention provides a composition for skin regeneration, which comprises soybean curd extract as an active ingredient.
상기 작두콩 추출물은 당업계에 공지된 방법에 의해 추출될 수 있으며, 그 방법은 특별히 한정되지 않는다. 또는, 시판되고 있는 추출물을 이용할 수 있다.The soybean extract can be extracted by a method known in the art, and the method is not particularly limited. Alternatively, commercially available extracts can be used.
바람직하기로는 상기 작두콩 추출물은 작두콩을 물 및/또는 유기용매로 추출하여 수득한 추출물을 사용할 수 있으며, 상기 유기용매는 극성 유기용매, 비극성 유기용매 또는 이들의 혼합용매일 수 있다. 상기 극성 유기용매는 탄소수 1 내지 5의 저급 알코올, 에틸아세테이트 또는 아세톤일 수 있으며, 비극성 유기용매는 에테르, 클로로포름, 벤젠, 헥산 또는 디클로로메탄일 수 있다. 예를 들어, 상기 탄소수 1 내지 5의 저급 알코올은 메탄올, 에탄올, 프로판올, 부탄올 또는 이소프로판올일 수 있다. Preferably, the soybean extract may be an extract obtained by extracting soybean curd with water and / or an organic solvent. The organic solvent may be a polar organic solvent, a nonpolar organic solvent or a mixture thereof. The polar organic solvent may be a lower alcohol having 1 to 5 carbon atoms, ethyl acetate or acetone, and the nonpolar organic solvent may be ether, chloroform, benzene, hexane or dichloromethane. For example, the lower alcohol having 1 to 5 carbon atoms may be methanol, ethanol, propanol, butanol or isopropanol.
한 구체예에서 상기 작두콩 추출물은 전술한 추출용매를 이용하여 추출된 1차 추출물을 극성이 다른 추출용매를 이용하여 분획한 분획물을 포함할 수 있다. 예를 들어, 작두콩 추출물은 탄소수 1 내지 5의 알코올로 추출한 후, 에테르, 벤젠, 헥산 등의 극성이 다른 용매로 다시 분획한 분획물일 수 있다. 상기 분획 시 용매는 2종 이상 사용할 수 있으며, 용매의 극성에 따라 순차적으로 사용하거나 혼합하여 사용하여, 각 용매 추출물을 제조할 수 있다. In one embodiment, the soybean extract may comprise a fraction obtained by fractionating the primary extract extracted using the above-described extraction solvent with an extraction solvent having a different polarity. For example, the soybean curd extract may be a fraction obtained by extracting with an alcohol having 1 to 5 carbon atoms and then fractionating again with a solvent having a different polarity such as ether, benzene or hexane. Two or more kinds of solvents may be used for the fractionation, and the solvent extracts may be sequentially used or mixed according to the polarity of the solvent.
본 발명에서, 상기 제조된 추출물 또는 상기 분획과정을 수행하여 수득한 분획물에 대해 여과하거나 농축 또는 건조과정을 수행하여 용매를 제거할 수 있으며, 상기 여과, 농축 및 건조를 모두 수행할 수 있다. 구체적으로 상기 여과는 여과지를 이용하거나 감압여과기를 이용할 수 있고, 농축은 감압 농축기 등을 이용하여 감압 농축할 수 있으며, 건조는 동결건조법을 수행할 수 있다. In the present invention, the extracted extract or the fraction obtained by performing the fractionation process may be filtered, concentrated or dried to remove the solvent, and the filtration, concentration, and drying may all be performed. Specifically, the filtration can be performed using a filter paper or a vacuum filter, and the concentration can be reduced by using a reduced pressure concentrator or the like, and the freeze-drying method can be carried out for drying.
또한, 상기 제조된 추출물 또는 상기 분획과정을 수행하여 수득한 분획물에 대해 실리카겔 컬럼 크로마토그래피(silica gel column chromatography), 박층 크로마토그래피(thin layer chromatography) 또는 고성능 액체 크로마토그래피(high performance liquid chromatography) 등의 다양한 크로마토그래피를 이용하여 정제함으로써 추가로 정제된 분획을 얻을 수 있다. The fractions obtained by performing the above-described extract or the fractionation process can be further purified by silica gel column chromatography, thin layer chromatography or high performance liquid chromatography Further purification can be achieved by purification using various chromatographic techniques.
본 발명의 조성물은 의약 제형 제조를 위해 사용할 수 있다.The compositions of the present invention may be used for the manufacture of pharmaceutical formulations.
상기 의약 제형은 오일 또는 수성 매질중의 용액, 현탁액 또는 유화액의 형태이거나, 엑스제, 분말제, 과립제, 정제 또는 캅셀제의 형태일 수 있다.The pharmaceutical formulations may be in the form of solutions, suspensions or emulsions in oils or aqueous media, or in the form of excipients, powders, granules, tablets or capsules.
또한, 상기 조성물은 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다. 예컨대, 공지의 피부 재생 성분을 포함할 수 있을 것이다. 추가적인 피부 재생 성분을 포함하게 되면 본 발명의 조성물의 피부 재생 효과는 더욱 증진될 수 있을 것이다. 상기 성분 추가 시에는 복합 사용에 따른 피부 안전성, 제형화의 용이성, 유효성분들의 안정성을 고려할 수 있다. 본 발명의 한 구체예에서, 상기 조성물은 당업계에 공지된 피부 재생 성분으로서, 레티노산, TGF, 동물 태반 유래의 단백질, 베튤린산 및 클로렐라 추출물, 당업계에 공지된 항산화 성분으로서, 토코페롤, 셀레늄, 비타민 C 및 페놀성 화합물, 당업계에 공지된 미백 성분으로서, 코지산(Kojic acid), 알부틴(Arbutin) 등과 같은 티로시나제 효소활성을 억제하는 물질, 하이드로퀴논(Hydroquinone), 비타민-C(L-Ascorbic acid) 및 이들의 유도체와 각종 식물 추출물로 구성되는 군으로부터 선택되는 1종 또는 2종 이상의 성분을 추가로 포함할 수 있다. 추가의 성분은 전체 조성물 중량에 대하여 0.0001 중량% 내지 10 중량%로 포함될 수 있을 것이며, 상기 함량 범위는 피부 안전성, 상기 작두콩 추출물의 제형화 시의 용이성 등의 요건에 따라 조절될 수 있을 것이다.In addition, the composition may further contain one or more active ingredients showing the same or similar functions. For example, a known skin regeneration component may be included. The skin regeneration effect of the composition of the present invention may be further enhanced by including an additional skin regeneration component. When the above ingredients are added, skin safety, easiness of formulation, and stability of effective ingredients can be considered according to the combined use. In one embodiment of the present invention, the composition is a skin regeneration component known in the art comprising retinoic acid, TGF, protein from animal placenta, betulinic acid and chlorella extract, antioxidant components known in the art, such as tocopherol, selenium , Vitamin C and phenolic compounds, whitening ingredients known in the art, substances inhibiting the activity of tyrosinase enzymes such as kojic acid and arbutin, hydroquinone, vitamin C (L- Ascorbic acid, derivatives thereof, and various plant extracts. The additional ingredients may be included in an amount of 0.0001% to 10% by weight based on the total weight of the composition, and the content range may be adjusted according to requirements such as skin safety, ease of formulation of the soybean extract.
또한, 본 발명의 조성물은 약학적으로 허용 가능한 담체를 더 포함할 수 있다.In addition, the composition of the present invention may further comprise a pharmaceutically acceptable carrier.
약학적으로 허용 가능한 담체는 완충액, 주사용 멸균수, 일반 식염수 또는 인산염 완충 식염수, 슈크로스, 히스티딘, 염 및 폴리솔베이트 등과 같은 여러 성분을 함유할 수 있다.Pharmaceutically acceptable carriers may contain a variety of ingredients such as buffer, injectable sterile water, normal saline or phosphate buffered saline, sucrose, histidine, salts and polysorbates, and the like.
본 발명의 조성물은 경구 또는 비경구로 투여할 수 있으며, 일반 약학 제제의 형태, 예를 들어, 임상 투여 시 경구 및 비경구의 여러 가지 제형으로 투여될 수 있는데, 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다.The composition of the present invention can be administered orally or parenterally, and can be administered in the form of a general pharmaceutical preparation, for example, various forms of oral and parenteral administration at the time of clinical administration. In the case of formulation, a filler, , A binder, a wetting agent, a disintegrant, a surfactant, and the like.
경구 투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 본 발명의 의약 조성물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘 카보네이트(Calcium carbonate), 수크로스(Sucrose) 또는 락토오스(Lactose), 젤라틴 등을 섞어 조제될 수 있다.Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like. These solid preparations can be prepared by mixing the pharmaceutical composition of the present invention with at least one excipient such as starch, calcium carbonate, Sucrose, lactose, gelatin and the like can be prepared.
단순한 부형제 이외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Examples of liquid formulations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used.
비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁용제로는 프로필렌 글리콜(Propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used as the non-aqueous solvent and suspension agent. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
본 발명에 있어서, '피부 재생 효과'라 함은 피부 외부 및 내부 원인에 의한 손상에 대하여 피부 조직이 회복되는 것을 말한다. 상기 외부 원인에 의한 손상은 자외선, 외부 오염 물질, 창상, 외상 등을 들 수 있으며, 상기 내부 원인에 의한 손상은 스트레스 등을 들 수 있다.In the present invention, the term " skin regeneration effect " refers to restoration of skin tissue against damage caused by external or internal causes of the skin. Damage due to external causes may include ultraviolet rays, external contaminants, wound, trauma, etc. The damage caused by the internal causes may be stress.
본 발명에 있어서, '유효량'이라 함은 손상된 피부의 재생을 촉진할 수 있는 추출물의 양을 의미한다. 본 발명의 조성물이 유효량의 상기 작두콩 추출물을 포함할 때 바람직한 피부 재생 효과를 제공할 수 있다. 본 발명의 조성물에 포함되는 상기 작두콩 추출물의 유효량은 조성물이 제품화되는 형태, 상기 화합물이 피부에 적용되는 방법 및 피부에 머무르는 시간 등에 따라 달라질 것이다. 예컨대, 상기 조성물이 약학 제형으로 제품화되는 경우에는 일상적으로 피부에 적용하게 되는 화장품으로 제품화되는 경우에 비해 높은 농도로 상기 작두콩 추출물을 포함할 수 있을 것이다. 따라서, 일일 투여량은 상기 작두콩 추출물의 양을 기준으로 0.1 내지 100 ㎎/㎏이고, 바람직하게는 30 내지 80 ㎎/㎏이고, 더욱 바람직하게는 50 내지 60 mg/kg이며, 하루 1 ∼ 6 회 투여될 수 있다. In the present invention, the term "effective amount" means the amount of the extract capable of promoting regeneration of damaged skin. When the composition of the present invention contains an effective amount of the soybean extract, it can provide a desirable skin regeneration effect. The effective amount of the soybean curd extract contained in the composition of the present invention will vary depending on the form in which the composition is produced, how the compound is applied to the skin, and the time on the skin. For example, when the composition is commercialized as a pharmaceutical formulation, it may contain a high concentration of the soybean curd extract as compared with a commercialized cosmetic product. Accordingly, the daily dose is 0.1 to 100 mg / kg, preferably 30 to 80 mg / kg, more preferably 50 to 60 mg / kg, based on the amount of the soybean extract, ≪ / RTI >
본 발명의 조성물은 단독으로, 또는 수술, 방사선 치료, 호르몬 치료, 화학 치료 및 생물학적 반응조절제를 사용하는 방법들과 병용하여 사용할 수 있다.The composition of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers.
본 발명의 의약 제형은 피부 외용제 제형을 포함할 수 있다. The pharmaceutical formulations of the present invention may include external preparation for skin.
상기 작두콩 추출물을 피부외용제로 사용하는 경우, 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 피부용 외용제에 통상적으로 사용되는 임의의 다른 성분과 같은 피부 과학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다. 또한 상기 성분들은 피부 과학 분야에서 일반적으로 사용되는 양으로 도입될 수 있다. When the soybean extract is used as an external preparation for skin, it may further contain at least one selected from the group consisting of fatty substances, organic solvents, solubilizers, thickening and gelling agents, softening agents, antioxidants, suspending agents, stabilizing agents, foaming agents, , Ionic or nonionic emulsifiers, fillers, sequestering agents and chelating agents, preservatives, vitamins, barrier agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or external preparations for skin ≪ / RTI > any other ingredients that are commonly used in the skin sciences. The components can also be introduced in amounts commonly used in the field of dermatology.
상기 작두콩 추출물이 피부 외용제 제형으로 제공될 경우, 이에 제한되는 것은 아니나, 연고, 패취, 겔, 크림 또는 분무제와 같은 제형을 가질 수 있다.When the soybean extract is provided as an external preparation for skin, it may have a formulation such as, but not limited to, ointments, patches, gels, creams or sprays.
또한, 본 발명의 피부 재생용 조성물은 화장료 제형 제조를 위해 사용될 수 있다.In addition, the skin regeneration composition of the present invention can be used for the production of cosmetic formulations.
상기 화장료 제형은 일반적인 유화 제형 및 가용화 제형의 형태일 수 있다. 예컨대, 유연 화장수 또는 영양 화장수 등과 같은 화장수, 훼이셜 로션, 바디로션 등과 같은 유액, 영양 크림, 수분 크림, 아이 크림 등과 같은 크림, 에센스, 화장연고, 스프레이, 젤, 팩, 선 스크린, 메이크업 베이스, 액체 타입, 고체 타입 또는 스프레이 타입 등의 파운데이션, 파우더, 클렌징 크림, 클렌징 로션, 클렌징 오일과 같은 메이크업 제거제, 클렌징 폼, 비누, 바디 워쉬 등과 같은 세정제 등의 제형을 가질 수 있다. The cosmetic formulation may be in the form of a conventional emulsion formulation and a solubilized formulation. For example, creams, essences, cosmetic creams, sprays, gels, packs, sunscreens, make-up bases, liquids such as lotions such as lotion, facial lotion, body lotion, A powder, a cleansing lotion, a makeup removing agent such as a cleansing oil, a cleansing foam, a soap, a body wash, and the like.
또한, 상기 화장품은 작두콩 추출물에 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다.The cosmetic composition may further contain, in addition to the soybean extract, a fat substance, an organic solvent, a solubilizing agent, a thickening agent and a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, Or any other conventionally used in cosmetics such as nonionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, barrier agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, ≪ RTI ID = 0.0 > ingredients. ≪ / RTI >
상기 화장료 제형은 유효성분이 단기간 내에 피부에 머무르게 되는 메이크업 제거제, 세정제 등과 같은 워쉬-오프(wash-off) 타입의 화장품의 경우에는 비교적 높은 농도의 상기 작두콩 추출물을 포함할 수 있을 것이다. 반면, 유효성분이 장기간 동안 피부에 머무르게 되는 화장수, 유액, 크림, 에센스 등의 리브-온(leave-on) 타입의 화장품의 경우에는 워쉬-오프 타입의 화장품에 비해 낮은 농도의 상기 작두콩 추출물을 포함해도 무방할 것이다. 이에 제한되는 것은 아니나, 본 발명의 한 구체예에서, 상기 조성물은 상기 작두콩 추출물을 전체 조성물 중량에 대하여 0.0001 중량% 내지 10 중량%(바람직하게는 0.0001 중량% 내지 1 중량%)로 포함할 수 있다. 본 발명의 조성물이 상기 작두콩 추출물을 0.0001 중량% 미만으로 포함할 경우에는 충분한 피부 재생 효과를 기대할 수 없고, 10 중량%를 초과하여 포함할 경우에는 알러지 등 원치 않는 반응이 발생하거나 피부 안전성에 문제가 있을 수 있으므로 이를 방지하기 위한 것이다.The cosmetic formulation may contain a relatively high concentration of the soybean curd extract in the case of wash-off type cosmetics such as a make-up remover, a detergent, etc. in which the active ingredient remains on the skin in a short period of time. On the other hand, in the case of leave-on type cosmetics such as lotion, cream, essence and the like in which the active ingredient remains on the skin for a long period of time, It will be acceptable. In one embodiment of the present invention, though not limited thereto, the composition may contain the soybean extract in an amount of 0.0001 wt% to 10 wt% (preferably 0.0001 wt% to 1 wt%) based on the total weight of the composition . If the composition of the present invention contains less than 0.0001% by weight of the soybean extract, sufficient skin regeneration effect can not be expected. If the composition contains more than 10% by weight, undesired reactions such as allergy or skin safety may occur This is to prevent this.
또한, 본 발명의 피부 재생용 조성물은 식품 제형 제조를 위해 사용될 수 있다.In addition, the skin regeneration composition of the present invention can be used for the production of food formulations.
상기 식품 제형은 상기 작두콩 추출물을 음료, 차류, 향신료, 껌, 과자류 등의 식품 소재에 첨가하거나, 캡슐화, 분말화, 현탁액 등으로 제조한 식품을 의미한다. The food formulation refers to a food prepared by adding the soybean curd extract to a food material such as beverage, tea, spice, gum, confectionery, or the like, or by encapsulation, powdering, suspension or the like.
상기 식품 제형은 일상적으로 섭취하는 것이 가능하기 때문에 높은 피부 재생 효과를 기대할 수 있어 매우 유용하다.Since the food preparation can be ingested on a daily basis, a high skin regeneration effect can be expected, which is very useful.
상기 작두콩 추출물을 식품첨가물로 사용하는 경우, 상기 작두콩 추출물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 혼합양은 그의 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조시에 본 발명의 조성물은 원료에 대하여 15 중량부 이하, 바람직하게는 10 중량부 이하의 양으로 첨가된다. 그러나, 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다.When the soybean curd extract is used as a food additive, the soybean curd extract can be directly added or used together with other food or food ingredients, and can be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to its intended use (prevention, health or therapeutic treatment). Generally, the composition of the present invention is added in an amount of not more than 15 parts by weight, preferably not more than 10 parts by weight, based on the raw material, when the food or beverage is produced. However, in the case of long-term consumption intended for health and hygiene purposes or for health control purposes, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range .
상기 식품의 종류에는 특별한 제한은 없다. 상기 물질을 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 초콜릿, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There is no particular limitation on the kind of the food. Examples of foods to which the above substances can be added include dairy products including meats, sausages, breads, chocolates, candies, snacks, confections, pizza, ramen noodles, gums, ice cream, soups, drinks, tea, Alcoholic beverages, and vitamin complexes, all of which include health foods in a conventional sense.
식품 제형이 음료인 경우, 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알코올이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 mL 당 일반적으로 약 0.01 ∼ 0.04 g, 바람직하게는 약 0.02 ∼ 0.03 g이다.When the food is a beverage, various flavors or natural carbohydrates may be added as an additional ingredient such as a normal drink. The above-mentioned natural carbohydrates are sugar alcohols such as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the composition of the present invention.
상기 외에 식품 제형은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 식품 제형은 천연 과일주스, 과일주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 혼합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물 100 중량부당 0.01 ~ 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the food formulations may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, And the like. Other food formulations may contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
본 발명은 또한, 상기 작두콩 추출물을 유효성분으로 포함하는 줄기세포 활성 촉진용 조성물을 제공한다.The present invention also provides a composition for stimulating stem cell activity comprising the soybean curd extract as an active ingredient.
본 발명에서 용어 ‘줄기세포’는 스스로 세포 분열을 할 수 있고, 매우 다양한 형태의 특이 세포 타입(specific cell type)으로 분화할 수 있는 능력을 갖는 세포이다. 이러한 줄기세포의 종류는 특별히 제한되지 않으며, 한 구체예에서, 상기 줄기세포는 피부줄기세포일 수 있다. 상기 ‘피부줄기세포’는 피부(표피, 진피 및 피하지방층)를 이루는 세포로 분화될 수 있는 줄기세포를 의미한다. 상기 피부를 이루는 세포는 표피에 존재하는 케라티노사이트(keratinocyte), 멜라노사이트(melanocyte) 및 진피에 존재하는 섬유아세포(콜라겐 및 엘라스틴의 생합성을 주로 담당)를 포함한다. The term 'stem cell' in the present invention is a cell capable of cell division by itself and capable of differentiating into a very specific type of specific cell type. The type of such stem cells is not particularly limited, and in one embodiment, the stem cells may be dermal stem cells. The term 'dermal stem cells' refers to stem cells that can be differentiated into cells constituting the skin (epidermis, dermis and subcutaneous fat layer). The cells that make up the skin include keratinocytes, melanocytes, and fibroblasts (mainly responsible for biosynthesis of collagen and elastin) present in the epidermis.
상기 피부줄기세포의 종류는 특별히 제한되지 않는다. 본 발명에서 사용되는 피부줄기세포는 그것이 어디로부터 유래한 것인지 관계없이 이용될 수 있다. 예를 들어, 피부줄기세포는 공지의 피부줄기세포 공급원, 예를 들어, 모낭 또는 표피의 기저층에서 얻을 수 있으며, 채취 대상인 동물은 포유동물일 수 있다. 한 구체예에서, 포유동물은 인간, 마우스, 랫트, 기니어 피그, 토끼, 원숭이, 돼지, 말, 소, 양, 영양, 개 또는 고양이를 포함할 수 있지만, 이에 한정되는 것은 아니다. 바람직하게 포유동물은 인간일 수 있다. 이러한, 피부줄기세포 공급원으로부터 피부줄기세포를 수득하는 방법에 대해서는 당업계에서 잘 알려져 있다.The kind of the skin stem cell is not particularly limited. The dermal stem cells used in the present invention can be used irrespective of where they originate from. For example, dermal stem cells may be obtained from a known source of dermal stem cells, e. G., From the basal layer of hair follicles or epidermis, and the animal to be harvested may be a mammal. In one embodiment, the mammal may include, but is not limited to, a human, a mouse, a rat, a guinea pig, a rabbit, a monkey, a pig, a horse, a cattle, a sheep, Preferably the mammal can be human. Such methods of obtaining dermal stem cells from dermal stem cell sources are well known in the art.
본 발명에 있어서, '줄기세포 활성 촉진 효과'라 함은 줄기세포 증식 촉진 효과 및/또는 줄기세포성 유지 효과를 포함하는 것을 말한다.In the present invention, 'stem cell activity promoting effect' refers to a stem cell proliferation promoting effect and / or a stem cell maintaining effect.
또한, 본 발명의 조성물은 화장료 제형 제조를 위해 사용될 수 있다. 이러한 화장료 제형에 대해서는 앞서 작두콩 추출물을 포함하는 화장료 제형에 관한 설명에 기재된 내용과 동일하다. In addition, the compositions of the present invention can be used for the production of cosmetic formulations. These cosmetic formulations are the same as those described in the description of cosmetic formulations including soybean curd extract.
이하, 본 발명을 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다. Hereinafter, the present invention will be described in detail with reference to examples. However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.
제조예Manufacturing example 1: 작두콩 추출물의 제조 1: Preparation of soybean extract
작두콩을 세척하고, 분말화한 뒤, 10 배의 에탄올(w/v)에서 5 일간 냉침한 후 추출 원액을 여과, 농축한 엑기스를 얻었다. 여기에 정제수 및 에탄올의 혼합용액을 첨가하여 용해시킨 다음 여과하여 최종 추출물을 제조하였다.The soybean curd was washed and pulverized, and then cooled in 10 times ethanol (w / v) for 5 days. The extract solution was filtered and concentrated to obtain an extract. To this was added a mixed solution of purified water and ethanol to dissolve and then filtered to prepare a final extract.
제조예Manufacturing example 2: 2: 무혈청Serum-free 배지조건에서Under medium conditions 피부줄기세포의Of dermal stem cells 배양 culture
Cellntec 사에서 구입한 인간 피부줄기세포(Human epidermal stem cell)를 96-웰 플레이트(5×103 cells/well)에, 소태아혈청(fetal bovine serum)과 유사한 BPE(Bovine pituitary extract)가 첨가된 CNT-57 배지(Cellntec 사)를 이용하여 24시간 동안 5% CO2 및 37℃ 조건에서 배양하였다. 그 후, 배양액을 흡입관을 통하여 제거한 다음, PBS 용액(GibcoBRL 사)을 이용하여 배지 성분을 제거하고, BPE가 포함되지 않은 CNT-57 배지에 작두콩 추출물 5㎍/ml을 처리하여 5％ CO2 및 37℃ 조건에서 72시간 동안 배양하였다.Human epidermal stem cells purchased from Cellntec were added to a 96-well plate (5 x 10 3 cells / well) supplemented with BPE (bovine pituitary extract) similar to fetal bovine serum And cultured for 24 hours at 5% CO 2 and 37 ° C using CNT-57 medium (Cellntec). Then, the culture fluid removed through the suction pipe, and then, PBS solution used to remove the medium components (GibcoBRL Co.), and the process to extract jakdukong 5㎍ / ml in the CNT-57 medium that does not contain a 5% CO 2 and BPE And cultured at 37 ° C for 72 hours.
실험예Experimental Example 1: One: CCKCCK -8 평가법을 통한 -8 Through evaluation method 피부줄기세포Dermal stem cells 증식 촉진 효과 Proliferation promoting effect
상기 제조예 2에서 배양된 피부줄기세포에 CCK-8(Cell counting kit-8) 평가를 실시하였다. CCK-8 평가는 세포 내 전자전달계 내의 탈수소효소(Dehydrogenase)가 테트라졸리움 염(Tetrazolium Salt)를 분해하여 생성하는 포르마잔(Formazan)의 흡광도를 측정하여 살아있는 세포의 밀도를 간접적으로 나타내는 분석방법이다. The skin stem cells cultured in Preparation Example 2 were evaluated for CCK-8 (Cell counting kit-8). The CCK-8 assay is an indirect method of measuring the density of living cells by measuring the absorbance of Formazan, a dehydrogenase in the intracellular electron transport system, produced by the decomposition of tetrazolium salt.
세포에 CCK-8 용액(배지부피의 1/10을 처리)을 37℃에서 2 시간 동안 처리한 후, 파장 450 nm에서의 흡광도를 측정함으로써 분광학적으로 측정하였다. 작두콩 추출물의 피부줄기세포의 증식 촉진 효과는 측정된 흡광도 값으로부터 대조군(추출물이 포함되지 않은 CNT-57 배지) 대비 하기 수학식 1에 따라 증식율(%)을 구하고, 그 값을 하기 표 1에 나타냈다.Cells were treated spectrophotometrically by treating CCK-8 solution (treated with 1/10 of the medium volume) at 37 ° C for 2 hours and then measuring the absorbance at 450 nm. From the measured absorbance value, the proliferation rate (%) of the soybean curd extract was determined according to the following equation (1) against the control group (CNT-57 medium without extract) .
[수학식 1][Equation 1]
증식율(%) = (시료처리군의 흡광도/대조군의 흡광도) × 100Growth rate (%) = (absorbance of sample-treated group / absorbance of control group) x 100
표 1에 나타난 바와 같이, 작두콩 추출물을 처리한 배지조건에서의 피부줄기세포는 우수한 증식 촉진 효과를 나타내었다. As shown in Table 1, skin stem cells under the medium conditions treated with soybean extract showed excellent proliferation promoting effect.
실험예Experimental Example 2: 2: 피부줄기세포의Of dermal stem cells 줄기세포성( Stem cell ( stemnessstemness ) 유지 효과 확인) Confirm maintenance effect
상기 제조예 2에서 배양된 피부줄기세포의 줄기세포성 유지 효과 확인을 위해 p63 발현 정도를 평가하였다. p63은 세포 내 전사인자로서 피부줄기세포의 유지 마커로 잘 알려져 있다. 세포의 RNA를 분리하여 cDNA를 합성한 다음, Taqman 염색액으로 실시간-PCR을 수행하여 p63의 발현 정도를 측정하였다. 본 실험에서 RNA의 농도는 S16 리보솜 RNA로 표준화하였다.The expression level of p63 was evaluated in order to confirm the stem cell maintenance effect of the dermal stem cells cultured in Production Example 2 above. p63 is an intracellular transcription factor and is well known as a maintenance marker for dermal stem cells. Cells were isolated and cDNA was synthesized. Then, real-PCR was performed with Taqman staining solution to measure the expression level of p63. The concentration of RNA in this experiment was normalized to S16 ribosomal RNA.
상기 실험 결과는 하기 표 2에 나타내었다. 하기 표 2에서 p63 증가 배수의 수치는 대조군(BPE 첨가한 CNT-57 배지) 대비 배수를 의미한다.The experimental results are shown in Table 2 below. In Table 2 below, the numerical value of the increase in p63 is a multiple of the control group (CNT-57 medium supplemented with BPE).
표 2에 나타난 바와 같이, 작두콩 추출물을 처리한 배지 조건은 피부줄기세포의 p63 발현을 촉진하여 줄기세포성 유지 효과가 우수하다.As shown in Table 2, the medium conditions treated with soybean extract of soybean curd promotes p63 expression in dermal stem cells, and thus has an excellent stem cell maintenance effect.
제제예Formulation example 1: 의약 제제의 제조 1: Manufacture of pharmaceutical preparations
1. 정제의 제조1. Preparation of tablets
작두콩 추출물 0.2㎎Soybean extract 0.2 mg
옥수수전분 100㎎100 mg of corn starch
유 당 100㎎100 mg of milk
스테아린산 마그네슘 2㎎ 2 mg of magnesium stearate
상기의 성분을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.
제제예Formulation example 2: 화장품의 제조 2: Manufacture of cosmetics
1. 영양크림의 제조1. Manufacture of nutritional cream
하기 조성과 같이, 작두콩 추출물을 유효성분으로 포함하는 영양크림을 통상의 방법에 따라 제조하였다.A nutritional cream containing the soybean curd extract as an active ingredient was prepared according to a conventional method, as shown below.
작두콩 추출물 0.2중량％0.2% by weight of soybean extract
베타-1,3-글루칸 5.0 중량％Beta-1,3-glucan 5.0 wt%
밀납 10.0 중량％Wax 10.0 wt%
폴리솔베이트60 1.5 중량％Polysorbate 60 1.5 wt%
피이지 60 경화피마자유 2.0 중량％≪ tb > < tb > < tb >
솔비탄세스퀴올레이트 0.5 중량％0.5% by weight of sorbitan sesquioleate
유동파라핀 10.0 중량％Liquid paraffin 10.0 wt%
스쿠알란 5.0 중량％Squalane 5.0 wt%
카프릴릭/카프릭트리글리세라이드 5.0 중량％Caprylic / capric triglyceride 5.0 wt%
글리세린 5.0 중량％Glycerin 5.0 wt%
부틸렌글리콜 3.0 중량％3.0% by weight of butylene glycol
프로필렌글리콜 3.0 중량％3.0% by weight of propylene glycol
트리에탄올아민 0.2 중량％0.2% by weight triethanolamine
방부제 0.05 중량％Preservative 0.05 wt%
색소 0.05 중량％0.05% by weight of pigment
향료 0.05 중량％0.05% by weight fragrance
정제수 to 100 중량％Purified water to 100%
제제예Formulation example 3: 피부 외용제의 제조 3: Preparation of external preparation for skin
1. 연고의 제조1. Manufacture of ointment
하기 조성과 같이, 작두콩 추출물을 유효성분으로 포함하는 연고를 통상의 방법에 따라 제조하였다.An ointment containing soybean curd extract as an active ingredient was prepared according to a conventional method, as follows.
작두콩 추출물 0.5 중량％0.5% by weight of soybean extract
베타-1,3-글루칸 10.0 중량%Beta-1,3-glucan 10.0 wt%
밀납 10.0 중량%Wax 10.0 wt%
폴리솔베이트60 5.0 중량%Polysorbate 60 5.0 wt%
피이지 60 경화피마자유 2.0 중량%≪ tb > < tb > < tb >
솔비탄세스퀴올레이트 0.5 중량%0.5% by weight of sorbitan sesquioleate
바셀린 5.0 중량%Vaseline 5.0 wt%
유동파라핀 10.0 중량%Liquid paraffin 10.0 wt%
스쿠알란 5.0 중량%Squalane 5.0 wt%
쉐어버터 3.0 중량%SHARE BUTTER 3.0 wt%
카프릴릭/카프릭트리글리세라이드 5.0 중량%Caprylic / capric triglyceride 5.0 wt%
글리세린 10.0 중량%Glycerin 10.0 wt%
프로필렌글리콜 10.2 중량%Propylene glycol 10.2 wt%
트리에탄올아민 0.2 중량%0.2% by weight triethanolamine
방부제 0.05 중량％Preservative 0.05 wt%
색소 0.05 중량％0.05% by weight of pigment
향료 0.05 중량％0.05% by weight fragrance
정제수 to 100 중량%Purified water to 100%
Claims (7)
A composition for regenerating skin comprising an extract of soybean curd as an active ingredient.
작두콩 추출물은 작두콩을 물 및 유기용매로 이루어진 군에서 선택된 하나 이상으로 추출하여 얻은 추출물인 피부 재생용 조성물.
The method according to claim 1,
Wherein the extract of soybean curd is an extract obtained by extracting soybean curd with at least one selected from the group consisting of water and an organic solvent.
유기용매는 탄소수 1 내지 5의 저급 알코올, 에틸아세테이트, 또는 아세톤을 포함하는 극성용매; 에테르, 클로로포름, 벤젠, 헥산 또는 디클로로헥산을 포함하는 비극성용매; 또는 이들의 혼합용매인 피부 재생용 조성물.
3. The method of claim 2,
The organic solvent may be a polar solvent containing a lower alcohol having 1 to 5 carbon atoms, ethyl acetate, or acetone; A nonpolar solvent comprising ether, chloroform, benzene, hexane or dichlorohexane; Or a mixed solvent thereof.
조성물은 피부 재생용 의약, 화장료 또는 식품 제조를 위한 것인, 피부 재생용 조성물.
The method according to claim 1,
Wherein the composition is for the manufacture of a medicament for skin regeneration, a cosmetic preparation or a food product.
A composition for stimulating stem cell activity, comprising a soybean extract as an active ingredient.
조성물은 줄기세포 증식 촉진 또는 줄기세포성 유지를 위한 것인, 줄기세포 활성 촉진용 조성물.
6. The method of claim 5,
Wherein the composition is for promoting stem cell proliferation or stem cell retention.
조성물은 줄기세포 활성 촉진용 화장료 제조를 위한 것인, 줄기세포 활성 촉진용 조성물.6. The method of claim 5,
Wherein the composition is for the production of a cosmetic for promoting stem cell activity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150121704A KR102577528B1 (en) | 2015-08-28 | 2015-08-28 | Composition for improving skin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150121704A KR102577528B1 (en) | 2015-08-28 | 2015-08-28 | Composition for improving skin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170025363A true KR20170025363A (en) | 2017-03-08 |
| KR102577528B1 KR102577528B1 (en) | 2023-09-12 |
Family
ID=58404299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150121704A KR102577528B1 (en) | 2015-08-28 | 2015-08-28 | Composition for improving skin |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102577528B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210010414A (en) * | 2019-07-19 | 2021-01-27 | 서울대학교산학협력단 | Cosmetic and functional food composition comprising caffeoylmalic acid having whitening and anti-photoaging activities |
| KR102248259B1 (en) * | 2020-05-04 | 2021-05-06 | 주식회사 바이오에프디엔씨 | Composition for skin improvement comprising Soybean plant cell-derived exosomes as an active ingredient |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08208424A (en) | 1994-12-20 | 1996-08-13 | Unilever Nv | Cosmetic composition containing betulinic acid |
| JPH08231370A (en) | 1995-02-23 | 1996-09-10 | Taiyo Kagaku Co Ltd | Skin cosmetic |
| JPH0940523A (en) | 1995-07-28 | 1997-02-10 | Ichimaru Pharcos Co Ltd | Fibroblast proliferation promoter containing water extract form chlorella |
| JPH1036283A (en) | 1996-07-18 | 1998-02-10 | Ichimaru Pharcos Co Ltd | Fibroblast proliferation promoting agent |
| KR20150007464A (en) * | 2013-07-11 | 2015-01-21 | 주식회사 바이오에프디엔씨 | Anti-aging and Anti-inflammatory and Anti-oxidant Cosmetic Composition including Beans Placenta Cell Cultures Extracts |
-
2015
- 2015-08-28 KR KR1020150121704A patent/KR102577528B1/en active IP Right Grant
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08208424A (en) | 1994-12-20 | 1996-08-13 | Unilever Nv | Cosmetic composition containing betulinic acid |
| JPH08231370A (en) | 1995-02-23 | 1996-09-10 | Taiyo Kagaku Co Ltd | Skin cosmetic |
| JPH0940523A (en) | 1995-07-28 | 1997-02-10 | Ichimaru Pharcos Co Ltd | Fibroblast proliferation promoter containing water extract form chlorella |
| JPH1036283A (en) | 1996-07-18 | 1998-02-10 | Ichimaru Pharcos Co Ltd | Fibroblast proliferation promoting agent |
| KR20150007464A (en) * | 2013-07-11 | 2015-01-21 | 주식회사 바이오에프디엔씨 | Anti-aging and Anti-inflammatory and Anti-oxidant Cosmetic Composition including Beans Placenta Cell Cultures Extracts |
Non-Patent Citations (9)
| Title |
|---|
| 1. Cardinale G. et al, Adv. Enzymol., 41, p. 425, 1974 |
| 2. Feingold 외, J. Invest. Dermatol., 110, pp 368-375, 1998. |
| 3. Feingold 외, J. Invest. Dermatol., 115, pp 353-360, 2000. |
| 4. Journal of the European Academy of Dermatology and Venereology. 12:103-114, 1999 |
| 5. The British journal of dermatology. 110: 129-138, 1984 |
| 6. Skin research and technology.5:189-194, 1999 |
| 7. Epidermal Stem Cells of the Skin, Cedric Blanpain, Elaine Fuchs, Annual Review of Cell and Developmental Biology, November 2006, Vol. 22, Pages 339-373 |
| 8. Human skin stem cells and the ageing process, Catherin Niemann, Stem Cell Aging and Regenerative Medicine, November 2008, Pages 986-997 |
| Immunology, 2008, Vol. 125, pp. 601-610* * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210010414A (en) * | 2019-07-19 | 2021-01-27 | 서울대학교산학협력단 | Cosmetic and functional food composition comprising caffeoylmalic acid having whitening and anti-photoaging activities |
| KR102248259B1 (en) * | 2020-05-04 | 2021-05-06 | 주식회사 바이오에프디엔씨 | Composition for skin improvement comprising Soybean plant cell-derived exosomes as an active ingredient |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102577528B1 (en) | 2023-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20170025375A (en) | Composition for improving skin | |
| KR20170025367A (en) | Composition for improving skin | |
| KR102577528B1 (en) | Composition for improving skin | |
| KR20170025355A (en) | Composition for improving skin | |
| KR101661288B1 (en) | Composition for improving skin | |
| KR102244585B1 (en) | Complex cosmetic composition for improving skin-aging | |
| KR20180060609A (en) | Composition for improving skin | |
| KR20180060611A (en) | Composition for improving skin | |
| KR20170025352A (en) | Composition for improving skin | |
| KR101872919B1 (en) | Composition for improving skin | |
| KR102183896B1 (en) | Composition for improving skin | |
| KR20180041108A (en) | Composition for improving skin | |
| KR20170025359A (en) | Composition for improving skin | |
| KR20170025350A (en) | Composition for improving skin | |
| KR20170025365A (en) | Composition for improving skin | |
| KR102472093B1 (en) | Composition for improving skin | |
| KR20170025356A (en) | Composition for improving skin | |
| KR20170025370A (en) | Composition for improving skin | |
| KR20170025364A (en) | Composition for improving skin | |
| KR20170025353A (en) | Composition for improving skin | |
| KR102013164B1 (en) | Composition for improving skin | |
| KR20180060607A (en) | Composition for improving skin | |
| KR20170099674A (en) | Composition for improving skin | |
| KR20170025371A (en) | Composition for improving skin | |
| KR20180060610A (en) | Composition for improving skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AMND | Amendment | ||
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application | ||
| X091 | Application refused [patent] | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant |